Topas Therapeutics will present Phase 2a clinical data for TPM502, a tolerizing nanoparticle therapy targeting celiac disease, at Digestive Disease Week 2025 in San Diego.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.